Form 8-K LEXICON PHARMACEUTICALS, For: Oct 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Lexicon Pharmaceuticals (LXRX) PT Raised to $6 at Leerink Partners
October 18, 2024 5:48 AM EDTLeerink Partners analyst Roanna Ruiz raised the price target on Lexicon Pharmaceuticals (NASDAQ: LXRX) to $6.00 (from $5.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: We see Lexicons (LXRX) exclusive licensing agreement with Viatris [VTRS, Not Rated, LINK] for sotagliflozin (sota) in all rest-of world (RoW) markets outside of US/Europe as... More
